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Abstract Autologous hematopoietic stem cell trans-
plantation (AHSCT) is a treatment option for relapsed and
recurrent follicular lymphoma (R/R FL); however, its value
in the rituximab era remains to be elucidated. To evaluate
the safety and clinical outcome of AHSCT for relapsed FL,
we present a retrospective series of AHSCT for 30 FL
patients (17 male and 13 female) at median age of
49 years. Patients were transplanted in second or sub-
sequent complete or partial response after at least one
therapeutic line including chemotherapy and rituximab.
Overall, seven patients achieved second or higher complete
response (CR) at AHSCT, whereas 23 were transplanted in
partial response. Median overall survival (OS) was not
reached, whereas progression-free survival (PFS) was
4.8 years. The estimated 10-year OS and PFS were found
to be 60 and 33 %, respectively. There was no significant
difference in OS and PFS in terms of FLIPI score and
disease status at transplant. Median follow-ups from diag-
nosis and from AHSCT were 4.9 years (range
1.5–18.4 years) and 1.7 years (range 0.03–16.5 years),
respectively. Fifteen patients relapsed, and 11 out of them
(73 %) died of disease recurrence and chemoresistance. At
the last contact, 19 patients are alive: 12 are in CR, whereas
seven patients receive salvage regimens due to active
lymphoma. AHSCT for relapsed FL patients who were
pretreated with rituximab remains a safe procedure with
low transplant-related mortality and long-term progression-
free survival in about one-third of transplanted patients.
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Introduction
Follicular lymphoma (FL) is a B-cell malignancy with an
indolent clinical course and characterized by lymphade-
nopathy, splenomegaly and bone marrow involvement.
Most patients are over 60 years at diagnosis and were
found to have t(14;18), resulting in the overexpression of
bcl-2 protein which is involved in apoptosis [1]. Most
asymptomatic FL patients at early disease stage do not
require treatment [2], whereas those with symptomatic
and advanced-stage disease receive chemotherapy plus
rituximab [3]. The value of autologous hematopoietic
stem cell transplantation (AHSCT) as a first remission
consolidation is to be established as the vast majority of
studies were performed in the pre-rituximab era. In sum,
the benefits were demonstrated in terms of progression-
free survival (PFS), but not in overall survival (OS) [4].
A large number of studies have shown some benefits of
AHSCT in R/R FL, but they have been conducted prior
to the widespread use of rituximab [5, 6]. Nevertheless,
AHSCT for R/R FL remains controversial and to date the
evidence-based data are lacking. The current indications
for AHSCT in R/R FL setting have been recently pro-
posed by expert panel of EBMT-Lymphoma Working
Party. The inclusion criteria for AHSCT in RR F/R are
as follows: patients in first and subsequent chemo-sensi-
tive relapse, especially those with a short duration of
response to immuno-chemotherapy and high FLIPI score
[7].
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Herein, we present the results of our 30 patients with
relapsed/recurrent FL who were performed AHSCT in our
center.
Patients and methods
Patient selection and characteristics
Thirty patients (17 male and 13 female) at median age of
49 years (range 21–69) underwent AHSCT between 1996
and 2011. The management of patients after diagnosis
followed common standards. A histological diagnosis was
established by a local pathologist using immunochemistry.
The disease stage was evaluated according to the Ann
Arbor staging system, and International Prognostic Index
for Follicular Lymphoma (FLIPI) score was calculated as
published elsewhere [8]. The diagnostic workup included
physical examination, complete blood count with differ-
ential, biochemistry studies, chest X-ray, abdominal ultra-
sonography, computed tomography of the neck, chest,
abdomen and pelvis. Bone marrow biopsy was taken at
diagnosis and in patients with primary marrow involve-
ment during response assessment. Patients were eligible for
AHSCT if they met the following criteria: (1) PR or second
or higher complete (CR) remission after conventional
immuno-chemotherapy, (2) ECOG status 0–2, (3) age
\70 years and (4) adequate hepatic, renal and cardiac
function. All patients signed informed consent. The clinical
characteristics of patients are presented in Table 1.
Treatment
Induction chemotherapy consisted of R-CHOP (rituximab,
cyclophosphamide, vincristine, adriamycin, prednisone; n =
12), R-CVP (n = 6) and CHOP/CVP (n = 12). Second- and
third-line therapeutic options included R-ESHAP (rituximab,
cisplatin, methylprednisolone, etoposide, cytarabine),
R-DHAP (rituximab, cisplatin, cytarabine, dexamethasone)
and R-FC (rituximab, fludarabine, cyclophosphamide) regi-
mens. All patients received at least one therapeutic line with
rituximab in pretransplant treatment. Overall, seven patients
achieved second or higher CR at AHSCT, whereas 23 were
transplanted in PR. Mobilized peripheral blood was the source
of stem cells for AHSCT in all patients. IVE (ifosfamide,
etoposide, epirubicin) was the most common regimen used for
mobilization. G-CSF (granulocyte colony stimulating factor)
at 10 ug/kg/day was started from day ?5 until the last day of
apheresis. The number of 2 9 106 CD34-positive cells/kg
was considered sufficient for AHSCT, but the number of
transplanted CD34-positive cells was below this threshold in
three patients. The apheresis product was processed, frozen to
-150C, stored and re-infused after completion of
conditioning. The preparative regimens included CBV
(cyclophosphamide, BCNU, etoposide) in 21 patients, BEAM
(BCNU, cytarabine, etoposide, melphalan) in four, and 90Y-
radiolabelled ibritumomab tiuxetan (zevalin) with BEAM (Z-
BEAM) in five.
Response criteria
The response to therapy was evaluated at 1, 3 and 6 months
after AHSCT and 6 months thereafter using CT. CR was
defined as a disappearance of all disease-related symptoms
and measurable lesions for at least 4 weeks; PR was
defined as a[50 % decrease in the sum of the products of
Table 1 Patient characteristics
Parameter FL (n = 30)
Male/female; no 17/13
Median age; years, range at diagnosis 49 (21–69)














Median number of treatment cycles; range 12 (6–22)
Rituximab containing regimen pre-AHSCT 30(100)
Radiotherapy prior AHSCT; no (%) 6 (20)
Median time to AHSCT; years, range 1.6 (0.7–6.5)
Disease status at AHSCT; no (%)
CR C 2 7 (23)
PR 23 (67)




Median days of post-AHSCT hospitalization; range 25 (18–35)
Median number of post-AHSCT blood transfusions;
range
2 (0–7)
Median number of post-AHSCT platelet
transfusions; range
3 (0–6)
AHSCT autologous hematopoietic stem cell transplantation; BEAM
BCNU, cytarabine, etoposide, melphalan; CBV cyclophosphamide,
BCNU, etoposide; CR complete response; FL follicular lymphoma;
PR partial response; Z zevalin
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the two largest diameters of all measurable lesions for at
least 4 weeks. A progressive disease was defined by any
increase [25 % in the sum of the diameter of any mea-
surable lesions or the appearance of a new lesion.
Statistical methods
The probability OS and PFS were calculated according to
Kaplan–Meier method. All calculations were made from
the date of transplantation. Comparisons between the
variables were carried out by log-rank test. Statistical sig-
nificance was defined at a p value \ 0.05. Transplant-
related mortality (TRM) was defined as death within
100 days of high-dose therapy not related to the disease,
relapse and progression.
Results
Cell dose and engraftment
The median number of transplanted nucleated cells was
3.3 9 108/kg (range 0.02–14.47), and the median number of
CD34-positive cells was 4.0 9 106/kg (range 1.1–26.9). All
patients engrafted. The median time to neutrophil recovery
was 12 days (range 10–22), and platelet count[50 9 109/L
was noted after median of 14 days (range 10–21).
Adverse events and supportive care
Thirteen patients demonstrated infectious complications at
the posttransplant period. Grade 3 or 4 nonhematological
adverse events were not observed. Five patients developed
fever with negative bacterial, and fungal cultures and mu-
cositis of grade 1 or 2 were observed in four cases. The other
complications included proctitis (n = 2), gastritis (n = 10),
pneumonia (n = 1) and laryngitis (n = 1). One patient died
within the first 100 days after AHSCT due to severe pul-
monary infection. Fourteen patients required G-CSF to
accelerate posttransplant regeneration. Median time of
posttransplant hospitalization was 25 days (range 18–35).
Outcome and prognostic factors
The TRM was 3 % at 100 day. Median OS was not
reached, whereas PFS was 4.8 years. The estimated
10-year OS and PFS were found to be 60 and 33 %,
respectively, see Fig. 1. There was no significant difference
in OS and PFS in terms of FLIPI score and disease status at
transplant. Median follow-ups from diagnosis and from
AHSCT were 4.9 years (range 1.5–18.4) and 1.7 years
(range 0.03–16.5), respectively. Fifteen patients relapsed,
and 11 out of 15 (73 %) died of disease recurrence and
resistance to chemotherapy. At the last contact, 19 patients
are alive: 12 are in CR, whereas 7 patients receive salvage
regimens due to active lymphoma.
Discussion
Autologous hematopoietic stem cell transplantation can
yield long-term disease-free survival when performed for FL
after relapse, and this seems to be true for both patients
treated in the pre-rituximab era and at the time of its wide
availability [9]. However, most studies on the results of
AHSCT for FL have been reported for patients who did not
obtain rituximab in their induction therapy. Of note is that
the vast majority of studied patients received total body
radiotherapy containing regimen as a high-dose therapy. The
OS and PFS at 10 years were 50 and 28 %, respectively,
with *20 % of patients being in CR 18 years after AHSCT
[10]. One of the largest nonrandomized studies reported on
the results of AHSCT for 248 recurrent FL patients. The
preparative regimen consisted of chemotherapy in 60 % of
OS for relapsed FL after AHSCT



























OS at 10 yrs= 60%; median OS = not reached
PFS for relapsed FL after AHSCT




























PFS at 10 yrs =33%; median PFS=4.8 yrs
Fig. 1 Overall and progression-free survival curves for relapsed FL
after autologous hematopoietic stem cell transplantation
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patients, and the remaining 40 % received radiotherapy. The
5-year OS and PFS were 63 and 44 %, respectively [11]. It
should be emphasized that despite the small number of
included patients to our study, the OS and PFS rates were
comparable with those obtained by other groups [10–12].
The significant advantage of AHSCT over standard
chemotherapy for R/R FL has been unquestionably deter-
mined in the only randomized study to date. The 5-year
PFS was 10 % in chemotherapy arm versus 55 % in the
transplant arm; there was also a significant benefit in terms
of OS in the latter one [6].
The addition of rituximab to conventional chemotherapy
in FL has improved outcome; however, the plateau on PFS
curves was not demonstrated [13]. Conversely, AHSCT for
relapsed FL may lead to eradication of a malignant clone in a
certain proportion of patients. Namely, the plateau on the
PFS curve was 50 % at 7.5 years [14]. In contrast, no plateau
was demonstrated by other reports [15] including ours.
It was also found that the use of AHSCT in first relapse of
FL regardless of prior exposure to rituximab has ameliorated
the 3-year OS [16]. A large prospective and randomized
study has been recently conducted to investigate the efficacy
of rituximab used both as in vivo purging before AHSCT and
as posttransplant maintenance. Median follow-up of 280
enrolled FL patients was 8.3 years. There was no difference
in 10-year PFS and OS between rituximab and no rituximab
arms in terms of pre-AHSCT purging. The addition of rit-
uximab as a maintenance treatment after AHSCT has sig-
nificantly prolonged PFS, but no OS if compared with
observation arm [17]. It remains unclear whether there is a
benefit of AHSCT for R/R FL patients who received prior
chemotherapy with rituximab as a first-line therapy. The
incorporation of rituximab into the transplant procedure may
decrease the risk of relapse via deeper reducing of tumor
burden before AHSCT [11]. The encouraging results were
obtained for R/R FL patients who were treated with immuno-
chemotherapy and in vivo purging before AHSCT with the
5-year PFS of 59 % [18].
Nevertheless, it was demonstrated that 3-year PFS after
AHSCT for rituximab-naı¨ve and rituximab-treated FL
patients was comparable (72 vs. 75 %, respectively). The
3-year OS rates were 92 % for both arms. A trend for better
3-year PFS rate after AHSCT was found for rituximab-
naı¨ve patients receiving rituximab at progression versus
those who did not receive rituximab at relapse (p = 0.07).
AHSCT was beneficial in terms of PFS and OS for ritux-
imab-treated FL patients if compared with those not
receiving transplantation (p = 0.052) [16]. To date, there
are no prospective studies that demonstrated the superiority
of AHSCT over conventional chemotherapy in the ritux-
imab era. Some single studies have shown a better disease
control in AHSCT arm, but it did not translate into better
OS [19]. It may be partially due to an increased risk of
secondary cancers after autograft [16]; however, this pre-
sumption has not been shown by others [20], including us.
It was concluded that radiotherapy as a preparative regimen
before AHSCT might be responsible for the development
of secondary malignancies and should be avoided [12]. In
our study, radiotherapy was not a part of conditioning and
no patient with secondary malignancy was detected after
maximum of more than 18 years of follow-up. 90Y-radio-
labeled ibritumomab tiuxetan was administered before
AHSCT in five patients, and it was well tolerated. As the
number of treated patients was low, it is difficult to draw
far-reaching conclusions. Nevertheless, three out of the five
treated patients are free of disease at the last contact.
In a majority of patients, the toxicity of transplant pro-
cedure was manageable and only one early posttransplant
death due to severe pulmonary infection was observed in
our study group. TRM at 100 days was 3 %. This finding is
in line with the TRM rates provided by other groups [15,
21]. There was no difference in the PFS and OS rates
regardless of FLIPI score and disease status at transplant.
The similar results have been demonstrated by other groups
[14]. Nevertheless, the following adverse risk factors for
predicting a worse OS were identified: grade 3 FL, high
FLIPI index at transplant and 3 or more chemotherapy lines
before AHSCT [11]. This finding, however, requires con-
firmation in other studies.
Conclusions
AHSCT for relapsed FL pretreated with rituximab remains
a safe procedure with low TRM and long-term progression-
free survival in about one-third of transplanted patients
with no plateau. It seems reasonable to offer AHSCT for
relapsed FL patients; however, its utility in the rituximab
era requires to be elucidated.
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